Safety, feasibility and immunogenicity
ADVERSE EVENTS
From December 2019 to August 2021, we enrolled 34 patients, of which 28 patients (Fig. None of the 19 patients treated with atezolizumab in the safety-evaluable cohort had grade 3 or higher adverse events (AEs; Fig. Next, to measure the T cell responses induced by autogene cevumeran, we utilized a previously described ex vivo IFNγ ELISpot assay